Report cover image

Global Drugs for Vulvovaginal Candidiasis Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031

Publisher GlobalInfoResearch
Published Jun 26, 2025
Length 99 Pages
SKU # GFSH20139274

Description

According to our (Global Info Research) latest study, the global Drugs for Vulvovaginal Candidiasis market size was valued at US$ 865 million in 2024 and is forecast to a readjusted size of USD 957 million by 2031 with a CAGR of 1.5% during review period.

The cell wall of Candida is a complex glycoprotein that depends on the biosynthesis of ergosterol. Azole compounds, found in antimycotic drugs, are believed to block ergosterol production, allowing topical antimycotics to achieve cure rates in excess of 80%. The only oral azole agent approved for this indication by the US Food and Drug Administration (FDA) is fluconazole, which also achieves a high cure rate. Therapeutic concentrations are found in vaginal secretions for at least 72 hours after the ingestion of a single 150-mg tablet.



Some women with recurrent candidal infections opt for treatment with over-the-counter (OTC) medications, which generally are highly effective for candidiasis. Preparations for intravaginal administration of butoconazole, clotrimazole, miconazole, and tioconazole are available OTC.

The main manufacturers of Drugs for Vulvovaginal Candidiasis are Bayer, J & J, Pfizer, Perrigo, Effik, etc. The top three manufacturers in the world occupy about 40% of the market share.

The Asia-Pacific region is the world"s largest market, with a market share of about 45%, followed by North America with nearly 20%

This report is a detailed and comprehensive analysis for global Drugs for Vulvovaginal Candidiasis market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.

Key Features:

Global Drugs for Vulvovaginal Candidiasis market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2020-2031

Global Drugs for Vulvovaginal Candidiasis market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2020-2031

Global Drugs for Vulvovaginal Candidiasis market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2020-2031

Global Drugs for Vulvovaginal Candidiasis market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (USD/Unit), 2020-2025

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Drugs for Vulvovaginal Candidiasis

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Drugs for Vulvovaginal Candidiasis market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Bayer, Perrigo, J & J, Pfizer, Bristol-Myers Squibb, Effik, Teva, Sanofi, Cisen Pharmaceutical, Kingyork Group, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market Segmentation

Drugs for Vulvovaginal Candidiasis market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
Cream
Pessary
Other

Market segment by Application
Hospital & Clinic
Pharmacy

Major players covered
Bayer
Perrigo
J & J
Pfizer
Bristol-Myers Squibb
Effik
Teva
Sanofi
Cisen Pharmaceutical
Kingyork Group

Market segment by region, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)

South America (Brazil, Argentina, Colombia, and Rest of South America)

Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Drugs for Vulvovaginal Candidiasis product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top manufacturers of Drugs for Vulvovaginal Candidiasis, with price, sales quantity, revenue, and global market share of Drugs for Vulvovaginal Candidiasis from 2020 to 2025.

Chapter 3, the Drugs for Vulvovaginal Candidiasis competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Drugs for Vulvovaginal Candidiasis breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.

Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.

Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Drugs for Vulvovaginal Candidiasis market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.

Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.

Chapter 13, the key raw materials and key suppliers, and industry chain of Drugs for Vulvovaginal Candidiasis.

Chapter 14 and 15, to describe Drugs for Vulvovaginal Candidiasis sales channel, distributors, customers, research findings and conclusion.

Table of Contents

99 Pages
1 Market Overview
2 Manufacturers Profiles
3 Competitive Environment: Drugs for Vulvovaginal Candidiasis by Manufacturer
4 Consumption Analysis by Region
5 Market Segment by Type
6 Market Segment by Application
7 North America
8 Europe
9 Asia-Pacific
10 South America
11 Middle East & Africa
12 Market Dynamics
13 Raw Material and Industry Chain
14 Shipments by Distribution Channel
15 Research Findings and Conclusion
16 Appendix
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.